ArticleFrontiers in oncology2024
Efficacy and prognosis biomarker of locally advanced ESCC patients treated with neoadjuvant chemotherapy and anti-PD-1 immunotherapy.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of neoadjuvant immunotherapy in locally advanced resectable esophageal squamous cell carcinoma: a network meta-analysis and real-world study.Frontiers in immunology · 2026Pooled it
- Development of a predictive model for pathological complete response following neoadjuvant immunotherapy and chemotherapy in locally advanced resectable esophageal squamous cell carcinoma.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immunotherapy has rapidly advanced in tumor treatment. In esophageal squamous cell carcinoma (ESCC), its use in neoadjuvant therapy has shown promising results. Several phase III clinical trials have confirmed that immunodetection site inhibitors in neoadjuvant therapy can enhance the pathologically complete response (pCR) rate. Methods: We retrospectively analyzed 128 ESCC patients treated with neoadjuvant chemotherapy plus anti-PD-1 immunotherapy at the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital from July 2019 to November 2023. Results: Of the 128 patients, 31 (24.1%) achieved pCR, and 46 (35.9%) achieved a major pathological response (MPR). Female patients, low-level tumor abnormal protein (TAP), and moderate differentiation were significantly associated with a higher pCR rate and MPR rate. Besides pCR rate and MPR rate, low-level TAP and moderate differentiation had significantly longer PFS and OS. The mean PFS in the low-level TAP group was 42.4 months, significantly longer than the 28.5 months in the high-level TAP group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.